Patents by Inventor Thomas J. Kipps

Thomas J. Kipps has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230341412
    Abstract: Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.
    Type: Application
    Filed: November 22, 2022
    Publication date: October 26, 2023
    Inventors: Thomas J. KIPPS, George F. WIDHOPF, II, Bing CUI
  • Publication number: 20230312708
    Abstract: Provided herein is a chimeric antigen receptor (CAR) and CAR-expressing immune cells that target human RORI expressed aberrantly on a tumor cancers. Described herein are chimeric antigen receptors that target human ROR-1, cell compositions expressing the chimeric antigen receptors, and methods and uses of the chimeric antigen receptors and/or the cell compositions. The chimeric antigen receptors described herein can be expressed by the T lymphocytes isolated from an individual afflicted with cancer and re-administered to the individual.
    Type: Application
    Filed: March 26, 2020
    Publication date: October 5, 2023
    Inventors: Charles E. PRUSSAK, Thomas J. KIPPS, George F. WIDHOPF, II, Christopher S. OH
  • Publication number: 20230192846
    Abstract: Provided herein are, inter alia, antibodies (e.g., humanized antibodies, monoclonal antibodies), antibody fragments (e.g., scFvs) and antibody compositions (e.g., chimeric antigen receptors, bispecific antibodies), which bind human tyrosine kinase-like orphan receptor 2 (ROR2) with high efficiency and specificity. The antibodies and antibody compositions provided herein include novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for diagnosing and treating cancer and other ROR2-related diseases.
    Type: Application
    Filed: November 18, 2020
    Publication date: June 22, 2023
    Inventors: Thomas J. KIPPS, George F. WIDHOPF
  • Patent number: 11654193
    Abstract: There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: May 23, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas J. Kipps, Liguang Chen, Bing Cui
  • Patent number: 11548953
    Abstract: Compositions including an antibody single-chain variable fragment (scFv) conjugate that specifically binds to ROR1 tumor-associated antigen are provided. The anti-ROR1 scFv antibody and conjugates may include a biologically-active molecule. Such conjugates may comprise a chimeric receptor to direct T cells to respond to ROR1 cancer cells, Methods to use the scFV conjugates to target cells expressing ROR1 for therapeutic and diagnostic purposes are also provided.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: January 10, 2023
    Assignee: The Regents of the University of California
    Inventors: Thomas J. Kipps, Jianqianq Yu
  • Patent number: 11536727
    Abstract: Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: December 27, 2022
    Assignee: The Regents of the University of California
    Inventors: Thomas J. Kipps, George F. Widhopf, II, Bing Cui
  • Publication number: 20210371535
    Abstract: Provided herein are, inter alia, methods of identifying agents that are capable of inhibiting the binding (e.g., coupling) between a ROR1 protein and a ROR2 protein. By interfering with ROR1-ROR2 coupling (binding) the agents identified using the methods provided herein inhibit non-canonical Wnt5a signaling. Thus, the agents identified by the methods provided herein may, inter alia, be useful for cancer diagnosis and therapy.
    Type: Application
    Filed: December 21, 2020
    Publication date: December 2, 2021
    Inventors: Thomas J. Kipps, Jian Yu
  • Publication number: 20210208158
    Abstract: Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.
    Type: Application
    Filed: December 22, 2020
    Publication date: July 8, 2021
    Inventors: Thomas J. Kipps, George F. Widhopf, II, Bing Cui
  • Publication number: 20210171655
    Abstract: Compositions including an antibody single-chain variable fragment (scFv) conjugate that specifically binds to ROR1 tumor-associated antigen are provided. The anti-ROR1 scFv antibody and conjugates may include a biologically-active molecule. Such conjugates may comprise a chimeric receptor to direct T cells to respond to ROR1 cancer cells, Methods to use the scFV conjugates to target cells expressing ROR1 for therapeutic and diagnostic purposes are also provided.
    Type: Application
    Filed: November 9, 2020
    Publication date: June 10, 2021
    Inventors: Thomas J. KIPPS, Jianqianq Yu
  • Patent number: 10921329
    Abstract: Complexes comprising a therapeutic monoclonal antibody and a peptide are provided. In some embodiments, the complexes may comprise a therapeutic monoclonal antibody which is not complexed to an epitope of a target protein and a peptide complexed to the therapeutic monoclonal antibody. In some embodiments, the peptide may have a length of about 5-40 amino acids and may comprise a mimetope recognized by the therapeutic monoclonal antibody, wherein the mimetope comprises a linear sequence of amino acids which is different than a linear sequence of amino acids in the epitope of the target protein.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: February 16, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas J. Kipps, Bradley T. Messmer, Ana B. Sanchez, Andrew C. Kummel, Manuel Ruidiaz
  • Publication number: 20210038716
    Abstract: There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.
    Type: Application
    Filed: May 8, 2020
    Publication date: February 11, 2021
    Inventors: Thomas J. Kipps, Liguang Chen, Bing Cui
  • Patent number: 10913798
    Abstract: Provided herein are, inter alia, methods of identifying agents that are capable inhibiting the binding (e.g., coupling) between a ROR1 protein and a ROR2 protein. By interfering with ROR1-ROR2 coupling (binding) the agents identified using the methods provided herein inhibit non-canonical Wnt5a signaling. Thus, the agents identified by the methods provided herein may, inter alia, be useful for cancer diagnosis and therapy.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: February 9, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas J. Kipps, Jian Yu
  • Patent number: 10900973
    Abstract: Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: January 26, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas J. Kipps, George F. Widhopf, II, Bing Cui
  • Publication number: 20200309785
    Abstract: Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.
    Type: Application
    Filed: January 30, 2020
    Publication date: October 1, 2020
    Inventors: Thomas J. Kipps, George F. Widhopf, II, Bing Cui
  • Patent number: 10688181
    Abstract: There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: June 23, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas J. Kipps, Liguang Chen, Bing Cui
  • Patent number: 10627409
    Abstract: Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: April 21, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas J. Kipps, George F. Widhopf, II, Bing Cui
  • Publication number: 20190324044
    Abstract: Methods for detection of any antibody utilizing a standardized approach applicable to any antibody which provides highly specific assays specific for individual or multiple antibodies. The methods enable improved pharmacokinetic analysis during development and clinical use of antibody-based therapies as well as determination of diagnostic and/or prognostic factors.
    Type: Application
    Filed: June 26, 2019
    Publication date: October 24, 2019
    Inventors: Thomas J. Kipps, Bradley T. Messmer, Ana B. Sanchez, Andrew C. Kummel, Manuel Ruidiaz
  • Patent number: 10359432
    Abstract: Complexes comprising a therapeutic monoclonal antibody and a peptide are provided. In some embodiments, the complexes may comprise a therapeutic monoclonal antibody which is not complexed to an epitope of a target protein and a peptide complexed to the therapeutic monoclonal antibody. In some embodiments, the peptide may have a length of about 5-40 amino acids and may comprise a mimetope recognized by the therapeutic monoclonal antibody, wherein the mimetope comprises a linear sequence of amino acids which is different than a linear sequence of amino acids in the epitope of the target protein.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: July 23, 2019
    Assignee: The Regents of the University of California
    Inventors: Thomas J. Kipps, Bradley T. Messmer, Ana B. Sanchez, Andrew C. Kummel, Manuel Ruidiaz
  • Publication number: 20180362657
    Abstract: Compositions including an antibody single-chain variable fragment (scFv) conjugate that specifically binds to ROR1 tumor-associated antigen are provided. The anti-ROR1 scFv antibody and conjugates may include a biologically-active molecule. Such conjugates may comprise a chimeric receptor to direct T cells to respond to ROR1 cancer cells, Methods to use the scFV conjugates to target cells expressing ROR1 for therapeutic and diagnostic purposes are also provided.
    Type: Application
    Filed: February 28, 2018
    Publication date: December 20, 2018
    Inventors: Thomas J. Kipps, Jianqianq Yu
  • Publication number: 20180348232
    Abstract: Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.
    Type: Application
    Filed: February 12, 2018
    Publication date: December 6, 2018
    Inventors: Thomas J. Kipps, George F. Widhopf, II, Bing Cui